爱博医疗
(688050)
| 流通市值：94.77亿 | | | 总市值：94.77亿 |
| 流通股本：1.93亿 | | | 总股本：1.93亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 398,242,787.56 | 1,482,702,741.33 | 1,144,414,504.11 | 786,691,059.79 |
| 营业收入 | 398,242,787.56 | 1,482,702,741.33 | 1,144,414,504.11 | 786,691,059.79 |
| 二、营业总成本 | 296,089,853.1 | 1,122,004,590.7 | 830,567,968.09 | 553,705,096.75 |
| 营业成本 | 153,399,566.14 | 541,288,873.75 | 402,855,805.65 | 273,336,318.16 |
| 税金及附加 | 4,798,020.3 | 18,460,774.21 | 14,524,603.64 | 9,836,857.48 |
| 销售费用 | 68,073,830.9 | 257,600,284.08 | 190,845,723.61 | 126,153,870.74 |
| 管理费用 | 44,407,025.07 | 189,667,113.53 | 138,244,210.16 | 87,238,347.07 |
| 研发费用 | 18,594,922.2 | 95,654,372.79 | 70,221,069.34 | 48,805,506.63 |
| 财务费用 | 6,816,488.49 | 19,333,172.34 | 13,876,555.69 | 8,334,196.67 |
| 其中:利息费用 | 5,824,547.23 | 22,984,026.27 | 16,985,417.16 | 11,763,805.79 |
| 其中:利息收入 | 865,220.39 | 3,065,611.06 | 2,158,484.64 | 1,687,721.39 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -323,548.67 | 198,097.41 | 120,847.64 | 95,216.94 |
| 加:投资收益 | 778,406.02 | 4,616,821.32 | 3,818,570.03 | 3,010,584.73 |
| 资产处置收益 | -81,535.62 | -93,893.98 | -216,522.16 | -141,563.74 |
| 资产减值损失(新) | 415,355.5 | -87,418,079.48 | -2,429,460.68 | -965,423.8 |
| 信用减值损失(新) | -8,215,214.94 | -11,224,000.8 | -11,297,561.92 | -8,426,877.17 |
| 其他收益 | 4,018,515.1 | 22,932,927.15 | 18,392,310.11 | 14,719,244.3 |
| 四、营业利润 | 98,744,911.85 | 289,710,022.25 | 322,234,719.04 | 241,277,144.3 |
| 加:营业外收入 | 126,517.07 | 735,048.83 | 579,234.09 | 459,728.77 |
| 减:营业外支出 | 225,356.66 | 1,182,751.71 | 409,250.84 | 179,373.74 |
| 五、利润总额 | 98,646,072.26 | 289,262,319.37 | 322,404,702.29 | 241,557,499.33 |
| 减:所得税费用 | 12,837,028.06 | 48,672,592.67 | 43,781,448.68 | 34,674,896.84 |
| 六、净利润 | 85,809,044.2 | 240,589,726.7 | 278,623,253.61 | 206,882,602.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 85,809,044.2 | 240,589,726.7 | 278,623,253.61 | 206,882,602.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 89,276,816.41 | 268,170,112.64 | 290,157,759.41 | 213,309,113.88 |
| 少数股东损益 | -3,467,772.21 | -27,580,385.94 | -11,534,505.8 | -6,426,511.39 |
| 扣除非经常损益后的净利润 | 88,581,231.64 | 255,230,141.03 | 279,595,704.74 | 204,271,068.12 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.46 | 1.4 | 1.51 | 1.12 |
| (二)稀释每股收益 | 0.46 | 1.4 | 1.51 | 1.12 |
| 八、其他综合收益 | 249,408.78 | 376,614.67 | -4,108,010.19 | -3,691,905.8 |
| 归属于母公司股东的其他综合收益 | 249,408.78 | 376,614.67 | -4,108,010.19 | -3,691,905.8 |
| 九、综合收益总额 | 86,058,452.98 | 240,966,341.37 | 274,515,243.42 | 203,190,696.69 |
| 归属于母公司股东的综合收益总额 | 89,526,225.19 | 268,546,727.31 | 286,049,749.22 | 209,617,208.08 |
| 归属于少数股东的综合收益总额 | -3,467,772.21 | -27,580,385.94 | -11,534,505.8 | -6,426,511.39 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |